RMD · Resmed Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free cash flow | $1.65B | FY 2026 | — |
| Non-GAAP diluted earnings per share non-GAAP | $11.17 | Twelve Months Ended June 30, 2026 | — |
| Non-GAAP gross margin non-GAAP | 62.4% | Twelve Months Ended June 30, 2026 | — |
| Non-GAAP selling, general, and administrative expenses non-GAAP | 19.6% | Twelve Months Ended June 30, 2026 | — |
| Operating cash flow | $1.81B | FY 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RMD
this stock
Resmed Inc
|
$31.83B | -4.2% | +13.4% | 21.2 | 10.9% |
|
ISRG
Intuitive Surgical Inc
|
$137.90B | -29.8% | +20.5% | 44.8 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$49.24B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$45.86B | -19.3% | +11.5% | — | 2.6% |
|
ALC
Alcon Inc
|
$35.55B | -5.8% | +10.5% | — | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RMD | +2.1% | +19.6% | -10.3% | +9.3% | -4.2% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +2.5% | +16.7% | -21.8% | +6.4% | -17.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.